Alessandra Ferrajoli

Q: What Schools Are Affiliated With Alessandra Ferrajoli

Alessandra Ferrajoli is affiliated with the following schools: MD Anderson Cancer Center

Alessandra Ferrajoli's AcademicInfluence.com Rankings

Medical

#2986

World Rank

#3435

Historical Rank

Hematology

#46

World Rank

#52

Historical Rank

medical Degrees

Alessandra Ferrajoli

Philosophy

#8606

World Rank

#12018

Historical Rank

Logic

#5641

World Rank

#7054

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Alessandra Ferrajoli's Degrees

Doctorate Medicine University of Milan

Why Is Alessandra Ferrajoli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alessandra Ferrajoli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007) (675)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. (2005) (535)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. (2008) (449)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. (2008) (430)
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. (2004) (400)
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. (2006) (371)
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. (2007) (340)
microRNA Therapeutics in Cancer — An Emerging Concept (2016) (335)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. (2014) (334)
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. (2010) (322)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. (2015) (318)
Ibrutinib and Venetoclax for First-Line Treatment of CLL. (2019) (306)
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. (2010) (297)
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. (2009) (290)
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies (2006) (288)
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. (2003) (254)
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia (2003) (242)
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. (2007) (236)
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. (2010) (236)
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. (2004) (228)
Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis (2003) (226)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. (2005) (218)
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens (2015) (216)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. (2008) (204)
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. (2010) (201)
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. (2013) (201)
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy (2003) (201)
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. (2003) (197)
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. (2013) (189)
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. (2017) (188)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. (2011) (184)
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. (2012) (181)
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. (2011) (171)
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. (2007) (171)
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. (2008) (169)
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. (2009) (164)
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. (2014) (161)
Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (2015) (158)
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. (2003) (157)
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia (2002) (156)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. (2018) (155)
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. (2006) (153)
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. (2013) (152)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. (2019) (150)
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration (2012) (148)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (2008) (144)
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. (2014) (138)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. (2020) (138)
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. (2007) (131)
Phase II study of alemtuzumab in chronic lymphoproliferative disorders (2003) (130)
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. (2011) (129)
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes (2015) (125)
Staging of chronic myeloid leukemia in the imatinib era (2006) (125)
Eradication of minimal residual disease in hairy cell leukemia. (2006) (121)
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. (2014) (116)
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase (2003) (113)
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers (2016) (113)
Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy (2018) (111)
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. (2009) (108)
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. (2002) (106)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chroni (2003) (106)
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy (2007) (105)
Activity of alemtuzumab in patients with CD52‐positive acute leukemia (2006) (102)
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome (2004) (101)
PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders (2007) (100)
Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib (2017) (98)
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. (2003) (96)
Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia (2016) (96)
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. (2018) (95)
The JAK-STAT pathway: a therapeutic target in hematological malignancies. (2006) (95)
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine (2008) (95)
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. (2007) (94)
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia (2011) (92)
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. (2009) (91)
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. (2011) (91)
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway (2018) (88)
Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen (2016) (88)
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. (2005) (87)
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. (2003) (87)
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. (2009) (87)
Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) (2014) (86)
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. (1992) (86)
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). (2014) (84)
Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies (2005) (83)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia (2017) (83)
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. (2001) (82)
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome‐positive chronic myelogenous leukemia (2003) (81)
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. (2015) (80)
Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (2011) (80)
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. (2017) (76)
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. (2013) (76)
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens (2006) (75)
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia (2003) (73)
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients (2008) (73)
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. (2011) (68)
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. (2006) (68)
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. (2014) (68)
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. (2009) (65)
Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia (2019) (65)
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. (2007) (64)
Invasive fungal infections in acute leukemia (2011) (63)
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion (2014) (63)
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. (2009) (63)
Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial (2016) (62)
STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells (2011) (62)
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (2012) (62)
Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (2018) (61)
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia (2021) (61)
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells (2015) (61)
The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients (2012) (60)
Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls (2004) (60)
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. (2005) (59)
Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients (2012) (59)
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. (2011) (59)
Clofarabine combinations as acute myeloid leukemia salvage therapy (2008) (58)
Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). (2007) (57)
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial (2016) (56)
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation (2018) (55)
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib (2007) (54)
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells (2013) (54)
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis (2015) (54)
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. (2010) (54)
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia (2009) (53)
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (2015) (53)
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia (2004) (53)
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. (2017) (53)
Alemtuzumab: a novel monoclonal antibody (2001) (52)
Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience (2004) (51)
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia (2018) (50)
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. (2011) (50)
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. (2006) (49)
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. (2014) (48)
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. (2016) (48)
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia (2018) (48)
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (2013) (48)
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia (2013) (48)
Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial (2010) (46)
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence (2010) (46)
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. (2020) (46)
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia (2016) (45)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib (2016) (43)
Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients (2013) (42)
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality (2020) (41)
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. (2018) (41)
Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival☆ (2015) (40)
Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP) (2008) (40)
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia (2004) (39)
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies (2017) (39)
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL. (2006) (39)
Role of angiogenesis in chronic lymphocytic leukemia (2006) (39)
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia (2010) (39)
Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia (2015) (39)
Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia (2008) (39)
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia (2008) (38)
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia (2005) (38)
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. (2007) (38)
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial (2017) (37)
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells (2018) (36)
Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. (2015) (36)
Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia (2013) (35)
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. (2007) (35)
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) (2017) (35)
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia (2017) (34)
Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome. (2005) (33)
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia (2003) (33)
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes (2010) (33)
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. (2011) (33)
Outcomes of patients with chronic lymphocytic leukemia treated with first‐line idelalisib plus rituximab after cessation of treatment for toxicity (2016) (33)
Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). (2009) (32)
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. (2021) (32)
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. (2020) (32)
Pleural effusions in patients with acute leukemia and myelodysplastic syndrome (2013) (31)
WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). (2005) (31)
Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma (2017) (30)
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia (2013) (30)
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. (2015) (30)
T-cell prolymphocytic leukemia: a single-institution experience. (2005) (29)
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia (2016) (29)
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. (2007) (29)
First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. (2018) (29)
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. (2007) (29)
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients (2019) (28)
FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). (2005) (28)
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies (2018) (28)
At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells (2016) (28)
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy (2019) (28)
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). (2006) (28)
Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. (1994) (27)
A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation (2018) (27)
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations (2018) (27)
The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab (2018) (27)
Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. (2007) (26)
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse (2006) (26)
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML (2016) (25)
Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. (2005) (25)
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review (2018) (25)
Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL) (2008) (24)
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors (2019) (24)
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics (2016) (24)
The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide (2018) (24)
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide (2015) (23)
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. (2004) (23)
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia (2018) (23)
Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL) (2017) (23)
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL. (2004) (23)
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. (2011) (22)
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3‐ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: Abstract: AML‐014 (2017) (22)
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia (2003) (22)
Suppression of chronic myelogenous leukemia colony growth by interleukin-4. (1993) (21)
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2019) (21)
Treatment of chronic lymphocytic leukemia. (2004) (21)
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) (2018) (21)
Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase (2018) (21)
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes. (2013) (21)
A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (2011) (21)
Soluble syndecan‐1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia (2009) (21)
Activation of the B‐cell receptor successively activates NF‐κB and STAT3 in chronic lymphocytic leukemia cells (2017) (21)
A phase 2 study of yttrium‐90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia (2009) (20)
A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy. (2004) (20)
Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens (2014) (20)
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. (2016) (20)
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments (2019) (20)
CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. (2008) (19)
Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib. (2004) (19)
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2022) (19)
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis (2019) (19)
Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML (2020) (19)
Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) (2008) (19)
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2018) (18)
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR) (2010) (18)
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia (2012) (18)
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. (2016) (18)
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. (2018) (18)
Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections (2017) (18)
β2‐microglobulin normalization within 6 months of ibrutinib‐based treatment is associated with superior progression‐free survival in patients with chronic lymphocytic leukemia (2016) (18)
Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis (1993) (18)
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. (2005) (17)
Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (17)
Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL). (2010) (17)
Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB) (2008) (17)
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study (2020) (17)
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy (2009) (17)
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome (2016) (16)
Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex (2017) (16)
Long‐term results of frontline dasatinib in chronic myeloid leukemia (2020) (16)
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. (2012) (16)
Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. (2005) (16)
Treatment of younger patients with chronic lymphocytic leukemia. (2010) (16)
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia (2016) (16)
Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine (2010) (16)
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia (2018) (16)
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial (2019) (16)
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia (2011) (16)
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia (2009) (16)
Chronic lymphocytic leukemia in African Americans (2012) (16)
CD 49 d Is the Strongest Flow Cytometry – Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia (2014) (16)
Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine (2020) (15)
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. (2011) (15)
Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2011) (15)
Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. (2010) (15)
Richter Syndrome in Chronic Lymphocytic Leukemia (2016) (15)
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53 (2019) (15)
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations (2021) (15)
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. (2019) (15)
Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia (2016) (15)
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). (2017) (14)
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients (2021) (14)
Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). (2005) (14)
STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis (2014) (14)
Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study (2014) (14)
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage (2019) (14)
Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities. (2007) (14)
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2019) (14)
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. (2014) (14)
Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. (2014) (14)
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. (1998) (14)
Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). (2004) (14)
Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia (2015) (13)
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. (2013) (13)
Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy (2017) (13)
Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia (2021) (13)
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia (2015) (13)
The involvement of microRNA in the pathogenesis of Richter syndrome (2018) (13)
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results (2020) (13)
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study (2018) (13)
Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. (2018) (12)
Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). (2005) (12)
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. (2020) (12)
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia (2014) (12)
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia (2018) (12)
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies (2007) (12)
Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial (2017) (12)
Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence (2010) (12)
Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. (2018) (12)
L‐carnitine and Vitamin B Complex for the Treatment of Pegasparaginase‐induced Hyperbilirubinemia (2018) (12)
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2019) (12)
Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). (2008) (11)
Treatment of Philadelphia chromosome–positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon‐alpha‐2b and low‐dose cytosine arabinoside (2003) (11)
Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma (2014) (11)
Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia (2020) (11)
The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment (2019) (11)
Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). (2007) (11)
Interferon‐α plus low‐dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients (1995) (11)
Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response. (2005) (11)
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome (2008) (11)
Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). (2009) (11)
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 (2019) (11)
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (2022) (11)
Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. (2019) (11)
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells (2011) (11)
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors (2021) (11)
A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib. (2009) (11)
Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL). (2006) (11)
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma (2021) (10)
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia (2020) (10)
Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML) (2010) (10)
Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations (2018) (10)
Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families. (2020) (10)
Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. (2020) (10)
The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. (2010) (9)
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy (2017) (9)
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. (2021) (9)
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia (2015) (9)
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure (2019) (9)
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia (2018) (9)
Prognostic Factors in the Era of Targeted Therapies in CLL (2018) (9)
SnapShot: chronic lymphocytic leukemia. (2014) (9)
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. (2022) (9)
PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study. (2004) (9)
Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). (2006) (8)
Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). (2005) (8)
Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). (2007) (8)
Chronic lymphocytic leukemia (2009) (8)
Interferon-α-Induced Biologic Modifications in Patients with Chronic Myelogenous Leukemia (1994) (8)
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome (2015) (8)
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia (2017) (8)
An Evidence‐based Review of Anti‐CD20 Antibody‐containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B‐cell Lymphoma, or Follicular Lymphoma (2018) (8)
The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL). (2006) (8)
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. (2019) (8)
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1] (2019) (8)
The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). (2006) (8)
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL) (2020) (8)
Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine (2013) (8)
Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases (2019) (8)
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia (2017) (8)
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). (2019) (7)
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells (2018) (7)
Postsplenectomy Cytomegaloviral Mononucleosis (2005) (7)
A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs). (2006) (7)
Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). (2009) (7)
Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma. (1990) (7)
Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. (2018) (7)
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia (2014) (7)
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). (2022) (7)
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation (2021) (7)
Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) (2008) (7)
Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib (2016) (7)
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab (2016) (7)
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia (2021) (7)
Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML) (2015) (7)
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia (2008) (7)
Usage of erythropoiesis‐stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia (2011) (7)
An Observational Study of the Occurrence of Atrial Fibrillation and Hypertension in Patients Treated with Ibrutinib (2014) (7)
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia (2017) (7)
Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Sub (2016) (6)
A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML). (2006) (6)
Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. (2019) (6)
Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors (1994) (6)
The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia (2020) (6)
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. (2008) (6)
Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). (2012) (6)
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures (2022) (6)
Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. (2009) (6)
Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. (2010) (6)
Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML). (2008) (6)
The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL (2020) (6)
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia (2019) (6)
A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia (2016) (6)
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience (2015) (6)
Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial (2020) (6)
Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia (2010) (6)
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality (2020) (6)
IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients. (1991) (6)
Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen (2012) (6)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs). (2009) (5)
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant (2020) (5)
Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib. (2008) (5)
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax (2020) (5)
Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy (2011) (5)
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia (2017) (5)
APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells. (2006) (5)
Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study (2020) (5)
Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens (2016) (5)
Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia (2011) (5)
Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia. (1994) (5)
A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia (2016) (5)
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL (2016) (5)
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia (2017) (5)
Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL. (2005) (5)
The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP) (2012) (5)
Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches. (1996) (5)
A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. (2007) (5)
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia (2015) (5)
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. (2022) (5)
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells (2019) (4)
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship (2017) (4)
A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia (2013) (4)
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis (2022) (4)
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (2013) (4)
Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2011) (4)
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets (2021) (4)
Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study. (2006) (4)
Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI) (2013) (4)
A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia (2017) (4)
Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage. (2006) (4)
Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL) (2014) (4)
Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL). (2019) (4)
Outcome of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation (2013) (4)
Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). (2010) (4)
Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL) (2008) (4)
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation (2018) (4)
Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial (2015) (4)
The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients (2008) (4)
Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML) (2014) (4)
Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (4)
Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance (2014) (4)
Central nervous system Richter’s transformation and parvovirus B19 infection (2013) (4)
Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). (2010) (4)
Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. (2014) (4)
Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (4)
Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML) (2013) (4)
Monoclonal antibodies in chronic lymphocytic leukemia (2006) (4)
Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB in Chronic Lymphocytic Leukemia Cells (2011) (4)
A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. (2010) (4)
Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) (2010) (4)
The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. (2006) (4)
Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia. (2008) (4)
Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11. (2008) (3)
Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. (2007) (3)
Bendamustine in relapsed or refractory chronic lymphocytic leukemia. (2005) (3)
Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB In Chronic Lymphocytic Leukemia (CLL) Cells (2010) (3)
Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial (2020) (3)
Long-term results of fi rst salvage treatment in CLL patients treated initially with FCR ( fl udarabine , cyclophosphamide , rituximab ) (2014) (3)
Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL). (2009) (3)
A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL, (2011) (3)
Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. (2019) (3)
Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL). (2012) (3)
Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study (2018) (3)
Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2021) (3)
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. (2019) (3)
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial (2022) (3)
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens (2019) (3)
Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission (2018) (3)
Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy (2011) (3)
Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2014) (3)
Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2 nd and 3 rd Tyrosine Kinase Inhibitors (TKIs) (2010) (3)
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study (2022) (3)
Incidence Rate Of Venous Thromboembolism (VTE) and Utilization Of a VTE Prophylaxis Order Set Module In Hospitalized Patients With Leukemia (2013) (3)
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis (2021) (3)
Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms (2012) (3)
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells (2021) (3)
Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP), (2011) (3)
Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) (2011) (3)
A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). (2022) (3)
Current guidelines in defining therapeutic strategies. (2004) (3)
Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia (2016) (3)
Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy (2012) (3)
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy (2019) (3)
WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells. (2004) (3)
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors (2022) (3)
A phase two study of high dose blinatumomab in Richter’s syndrome (2022) (3)
Phase1Study of ABT-751, a NovelMicrotubule Inhibitor, in Patients with Refractory HematologicMalignancies (2005) (3)
CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia (2013) (3)
Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic (2020) (3)
Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. (2007) (3)
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL) (2012) (3)
Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia (2015) (3)
A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2017) (2)
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results (2021) (2)
Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience (2016) (2)
Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease (2021) (2)
Deletion 11q Abnormality in Patients With Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (Clinical and Radiological) at Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients With CLL and del11q Cytogenetic Abnormality (2013) (2)
Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19 (2021) (2)
Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia (2013) (2)
Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab. (2005) (2)
Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL) (2014) (2)
Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies (2022) (2)
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma (2016) (2)
Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia (2013) (2)
Chemotherapy of Chronic Lymphocytic Leukemia (2004) (2)
Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. (2018) (2)
61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020 (2020) (2)
Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL) (2010) (2)
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2019) (2)
Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia (2014) (2)
Hippo Pathway (HP) Activity In Acute Myelogenous Leukemia (AML): Different Prognostic Implications Of TAZ versus YAP Inactivation By Phosphorylation (2013) (2)
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax (2021) (2)
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Chemoimmunotherapy. (2005) (2)
Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience (2013) (2)
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype (2019) (2)
A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia (2021) (2)
Early Ofatumumab Treatment For High-Risk, Treatment-Naive Patients With Chronic Lymphocytic Leukemia (2013) (2)
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement (2019) (2)
Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. (2006) (2)
Hepatitis c virus infection risk tool for patients with cancer. (2018) (2)
Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia (2015) (2)
Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission (2021) (2)
Hepatitis B reactivation after chemoimmunotherapy: screen before treatment (2021) (2)
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. (2017) (2)
Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. (2009) (2)
Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups (2021) (2)
Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML). (2010) (2)
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells (2022) (2)
The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide (2015) (2)
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia (2016) (2)
Preliminary Results of Phase I Trial of Sphingosomal Vincristine (SV) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). (2004) (2)
A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission (2021) (2)
Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin (2015) (2)
Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. (2014) (2)
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia (2021) (2)
Unusual complications in the management of chronic lymphocytic leukemia (2022) (1)
Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort (2020) (1)
Variations in Proteasome Enzymatic Activities in Plasma of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and Their Value in Predicting Clinical Behavior. (2006) (1)
Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience (2016) (1)
INSIDE‐OUT VLA‐4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE (2017) (1)
WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL. (2005) (1)
Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML) (2016) (1)
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. (2015) (1)
Models predictive for survival in untreated patients with CLL at initial presentation and initial treatment (2005) (1)
Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials (2020) (1)
Epidermal Growth Factor Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia. (2006) (1)
Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up (2018) (1)
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib. (2021) (1)
Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia (2010) (1)
Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP). (2016) (1)
Genomics STAT 3-Activated GM-CSFR a Translocates to the Nucleus and Protects CLL Cells from Apoptosis (2014) (1)
5.59 Lenalidomide Induces Long-lasting Responses in Elderly Patients with Chronic Lymphocytic Leukemia (2011) (1)
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (2021) (1)
Measurement and Clinical Relevance of Proteasome Enzymatic Activity in Plasma of Patients with Acute Lymphoblastic Leukemia. (2006) (1)
Unusual complications in the management of CLL. (2022) (1)
IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment (2015) (1)
Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes (2016) (1)
Chemoimmunotherapy for Patients with Chronic Lymphocytic Leukemia: MD Anderson Experience Beyond FCR300 (2016) (1)
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. (2023) (1)
Hematological Malignancies (2004) (1)
Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure (2015) (1)
Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL (2010) (1)
Symptom profiles in patients with chronic lymphocytic leukemia: validation and application of the M. D. Anderson Symptom Inventory (2010) (1)
Chronic Lymphocytic Leukemia (2020) (1)
Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL) (2016) (1)
Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy (2020) (1)
EFFECT OF IFNα THERAPY ON SECONDARY Ph1‐POSITIVE CLONES (1992) (1)
High T-Cell Lymphoma Breakpoint 1 (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL). (2008) (1)
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia (2018) (1)
Variations in Proteasome Enzymatic Activities in Plasma of Patients with Chronic Lymphocytic Leukemia and Their Value in Predicting Clinical Behavior. (2006) (1)
Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine (2020) (1)
Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC) (2011) (1)
Abnormal expression of FLI 1 protein is an adverse prognostic factor in acute myeloid leukemia (2011) (1)
PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study. (2006) (1)
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia (2020) (1)
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial (2021) (1)
Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells (2019) (1)
Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia The M.D Anderson Cancer Center Experience. (2005) (1)
Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia. (2006) (1)
Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents (2015) (1)
Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo (2016) (1)
untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously (2013) (1)
The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells. (2007) (1)
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data (2022) (1)
Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders. (2005) (1)
Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-Line FCR (2018) (1)
Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab (2010) (1)
Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells (2015) (1)
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First‐Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p: Abstract: CLL‐018 (2017) (1)
Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia (2015) (1)
Treatment with Lenalidomide (Revlimid ® ) Upregulates CD40 Expression on CLL Cells and Increases Their Sensitivity to CD40-Mediated Cytotoxicity in Vitro (2008) (1)
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient? (2022) (1)
Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. (2007) (1)
Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction (2013) (1)
Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) (2014) (1)
Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML) (2011) (1)
Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C). (2005) (1)
Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells (2017) (1)
Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion, (2011) (1)
Growth factors controlling interleukin-4 action on hematopoietic progenitors (1993) (1)
Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia (2012) (1)
Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy (2015) (1)
Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). (2009) (1)
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. (2023) (0)
Janus Kinase (JAK)-2 Does Not Play a Role in Bcr-Abl Signaling in Philadelphia Chromosome (Ph)-Positive (p190) Acute Lymphoblastic Leukemia (ALL) Cells. (2007) (0)
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy (2021) (0)
CML-217: Low-Dose Dasatinib 50 mg Daily Versus Standard-Dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis (2020) (0)
Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR) (2017) (0)
The Natural History and Treatment Outcome of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients. (2007) (0)
Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia (2018) (0)
**107 Monitoring of Innate Cellular Immune Responses in Chronic Lymphocytic Leukemia (CLL)-A Pilot Study (2011) (0)
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML (2014) (0)
Atiprimod Blocks STAT3 and STAT5 Phosphorylation, Inhibits Proliferation, and Induces Apoptosis in Acute Myeloid Leukemia (AML) but Not Normal Cells. (2005) (0)
A longitudinal monitoring of left ventricular ejection fraction (LVEF) during reduced dosing anthracycline based chemotherapy in patients with breast cancer. (2018) (0)
IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL) (2015) (0)
Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse (2012) (0)
WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples. (2004) (0)
Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen (2011) (0)
Brief report Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans (2012) (0)
Optimization Of Behavioral Interventions For Patients With Chronic Lymphocytic Leukemia: The HEALTH4CLL Study (2022) (0)
Clinical Significance of Free Circulating CD3 and CD5 in Patients with Chronic Lymphocytic Leukemia. (2006) (0)
Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial (2020) (0)
CD20 Antigen Expression Is Increased in Trisomy 12 CLL as Compared to Other Cytogenetic Subtypes. (2006) (0)
Normalization of B2-microglobulin During the First Year of Treatment is Predictive for Prolonged Progression-free and Overall Survival in CLL Treated with FCR or Ibrutinib-based Regimens (2015) (0)
Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center (2022) (0)
4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients (2011) (0)
Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab (2021) (0)
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). (2019) (0)
Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study (2015) (0)
Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. (2008) (0)
Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones (2021) (0)
Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS). (2005) (0)
Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia (2016) (0)
Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience (2012) (0)
253 Tolerability of high-dose cyclophosphamide and carboplatinum followed by GM-CSF infusion (1995) (0)
1120 Factors that influence peripheral blood stem cell harvest after high-dose cyclophosphamide and carboplatin followed by GM-CSF infusion (1995) (0)
Issue information (2015) (0)
Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience (2017) (0)
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia (2018) (0)
3.19 Disease Characteristics and Response to First Therapy in African American Patients with CLL: the M.D. Anderson Cancer Center Experience (2011) (0)
Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. (2008) (0)
Haematological, cytogenetic and molecular response in CKL patients treated with high-dose chemotherapy at diagnosis, in the accelerated phase or blastic crisis (1993) (0)
Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI). (2016) (0)
Management of chronic lymphocytic leukemia in elderly patients (2014) (0)
Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells (2021) (0)
Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib (2018) (0)
Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients with Cancer: Retrospective Chart Review (2018) (0)
Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase (2017) (0)
Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. (2020) (0)
PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM). (2006) (0)
Interleukin-1 Receptor Antagonist and Interleukin-1 beta: Different Roles in Patients with Chronic Lymphocytic Leukemia. (2006) (0)
Predictors of survival in patients with transformed chronic lymphocytic leukemia (TC). (2013) (0)
Signal Transducer and Activator of Transcription (STAT)-3 Induces Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Receptor-α Expression in Chronic Lymphocytic Leukemia (CLL) Cells, (2011) (0)
Incidence, Clinical Features and Outcome of Patients with Differentiation Syndrome in Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid (ATRA) Alone Versus ATRA Plus Idarubicin Versus ATRA Plus Arsenic Trioxide. (2009) (0)
Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia. (2005) (0)
Clinical impact of dose intensity of initial tyrosine kinase inhibitor (TKI) therapy in accelerated-phase CML (CML-AP). (2012) (0)
Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells (2016) (0)
Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL) (2020) (0)
Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients (2019) (0)
Long-term cytogenetic response to IFN-α, IFN-α followed by the association with low-dose ARA-C or high-dose chemotherapy in CML patients (1993) (0)
Lenalidomide in chronic lymphocytic leukemia (2016) (0)
Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase (2014) (0)
PS1139 P300 INDUCES STAT3 ACETYLATION AND PROVIDES CLL CELLS WITH SURVIVAL ADVANTAGE (2019) (0)
A Phase Ib Pilot Study of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL) (2021) (0)
Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (0)
Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful? (2019) (0)
Incidence Rate of Venous Thromboembolism (VTE) and Utilization of a VTE Prophylaxis Orderset Module In Hospitalized Patients With Leukemia (2015) (0)
Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study (2020) (0)
Long-term follow-up results of hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL) (2004) (0)
Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia, (2011) (0)
Favorable outcome with hyper-CVAD in lymphoblastic lymphoma (LL). (2004) (0)
High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL) (2022) (0)
Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL) (2010) (0)
M interleukin-1 ( IL-1 ) receptor antagonist and soluble IL-1 receptors Inhibition of acute myelogenous leukemia blast proliferation (2003) (0)
Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS) (2010) (0)
Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. (2012) (0)
Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study (2022) (0)
Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) (2017) (0)
Assessment of Immunoglobulin Heavy Chain Variable Region (IGHV) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD) (2021) (0)
Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase (2018) (0)
Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib (2022) (0)
ALL-326: Low Incidence of Central Nervous System (CNS) Relapse with Hyper-CVAD-R Regimen in Adults with Burkitt Lymphoma/Leukemia (BL) and High-Grade B-Cell Lymphoma (HGBCL) (2020) (0)
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. (2023) (0)
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs) (2019) (0)
Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL (2015) (0)
Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia (2020) (0)
Other Cancers in CLL, a Common Problem (2017) (0)
CHARACTERISTICS OF PLEURAL EFFUSIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2020) (0)
Identification of B cell receptor antigens in the chronic lymphocytic leukemia microenvironment. (2015) (0)
Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation (2011) (0)
A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up (2022) (0)
Treatment options for refractory chronic lymphocytic leukemia (2012) (0)
Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (2012) (0)
myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute (2013) (0)
Nilotinib or Dasatinib Front-Line Therapy in Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-existing Liver and/or Renal dysfunction (2014) (0)
Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p). (2013) (0)
Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies (2016) (0)
Effect of IFN alpha therapy on secondary Ph1-positive clones. (1992) (0)
Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells (2019) (0)
STAT3 Is Constitutively Phosphorylated on Serine 727 Residues, Activates Transcription, and Plays a Major Role in the Pathogenesis of B-Cell Chronic Lymphocytic Leukemia. (2008) (0)
Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)? (2015) (0)
Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL) (2014) (0)
Clinical Significance of del11q FISH% in Patients With Chronic Lymphocytic Leukemia (CLL) – Can it Impact Prognostication in the Routine Clinical Practice? – Comprehensive Analysis From MD Anderson Cancer Center (2014) (0)
CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment (2016) (0)
Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO). (2010) (0)
Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder (2021) (0)
Long-Term Follow-Up of Patients with T-Large Granular Lymphocyte Leukemia (T-LGL); Experience in a Single Institution. (2005) (0)
Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) (2022) (0)
STAT3-Activated GM-CSFRα Shuttles To The Nucleus and Protects CLL Cells From Apoptosis (2013) (0)
Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin (2015) (0)
Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML) (2013) (0)
T-cell prolymphocytic leukemia: 17-year experience at a single institution (2004) (0)
Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy (2021) (0)
Importin-β1 and Nucleus Transporter Chromosome Region Maintenance 1 (CRM1) Constitute the Nucleocytoplasmic Transport System of STAT3 in Blood-Derived CLL Cells. (2008) (0)
P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells (2015) (0)
A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. (2023) (0)
Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia (2003) (0)
Author reply (2006) (0)
Constitutively Serine Phosphorylated STAT3 Provides Chronic Lymphocytic Leukemia (CLL) Cells with Survival Advantage and Promotes Their Proliferation. (2007) (0)
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study (2023) (0)
Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib (2020) (0)
Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene. (2019) (0)
Signal transducer and activator of transcription (STAT)-3 is a double edged sword in CLL cells (2015) (0)
Characteristics, Response to Therapy and Outcome of African American Patients With Chronic Lymphocytic Leukemia (2013) (0)
Comparison of normal saline versus heparin flush solutions for maintaining patency of central venous catheter in cancer patients. (2019) (0)
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells (2013) (0)
Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib. (2010) (0)
Chemotherapy Use within the Last 14 Days of Life in Patients with Hematological Malignancies (2012) (0)
Other cancers in long-term survivor patients with chronic lymphocytic leukemia (2015) (0)
Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma (2016) (0)
Other Cancers in Patients With Chronic Lymphocytic Leukemia Requiring Therapy: Association With Prognostic Factors and Impact on Survival (2012) (0)
Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). (2018) (0)
A Novel, Clinically Adaptable Comorbidity Assessment Tool for Non-Hodgkin Lymphoma (NHL), the Three-Factor Risk Estimate Scale (TRES): Analysis of 40,000 Older Adults Enrolled in SEER-Medicare (2022) (0)
Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (0)
Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2016) (0)
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring (2023) (0)
Efficacy of immune checkpoint inhibitors for the treatment of metastatic melanoma (MM) in patients with concurrent chronic lymphocytic leukemia (CLL). (2020) (0)
STAT3-Driven, Aberrantly Expressed Lipoprotein Lipase Mediates Free Fatty Acid Metabolism in Chronic Lymphocytic Leukemia Cells (2014) (0)
Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response (2018) (0)
The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis (2020) (0)
The Role of Monoclonal Antibodies in the Management of Leukemia (2010) (0)
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. (2023) (0)
PS1180 FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) (2019) (0)
Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. (2012) (0)
Acute Myeloid Leukemia in the Elderly : A Unique Disease November (2017) (0)
T-cell prolymphocytic leukemia: 17-year experience at a single institution. (2004) (0)
Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs (2018) (0)
Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide (2015) (0)
Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS). (2006) (0)
Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors. (2006) (0)
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia (2021) (0)
Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL) (2015) (0)
Identification of novel B cell receptor antigens in chronic lymphocytic leukemia. (2016) (0)
CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB (2018) (0)
Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year (2022) (0)
Cytogenetic response to intensive chemotherapy in chronic myelogenous leukemia patients (1993) (0)
Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage (2018) (0)
CLL and Fat Cells Utilize Similar Metabolic Pathways (2017) (0)
Acute Myeloid Leukemia in the Elderly: A Unique Disease (2006) (0)
CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells (2021) (0)
Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes (2012) (0)
Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL (2019) (0)
Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. (2017) (0)
CLL-229: Efficacy of Immune Checkpoint Inhibitors in Metastatic Melanoma (MM) Patients with Concurrent Chronic Lymphocytic Leukemia (CLL) (2020) (0)
Abstract 801: Expression of BCL2 alternative proteins and association with outcome in CLL patients with venetoclax (2020) (0)
Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies. (2006) (0)
Pretreatment prognostic factors associated with outcomes for first-line FCR-based treatments in previously untreated CLL. (2012) (0)
Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3. (2009) (0)
Stimulation of the B-Cell Receptor (BCR) Induces Tyrosine Phosphorylation of STAT3 via NF-κB Dependent Mechanism (2016) (0)
Long-term follow-up results of hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). (2004) (0)
Venetoclax combined with cladribine in patients with relapsed/refractory (R/R) T-cell prolymphocytic leukemia (T-PLL). (2022) (0)
Signal Transducer and Activator Of Transcription 3 Activates and Deregulates Micro RNA Expression In Chronic Lymphocytic Leukemia Cells (2013) (0)
The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All–Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO). (2009) (0)
Association of Non-Hodgkin Lymphoma (NHL), Comorbidity and Death Due to Other Cancers in 30,000 Older Adults from SEER-Medicare (2022) (0)
AML-410: Efficacy of Hyperbaric Oxygen Therapy in Hematologic Malignancy Patients: A Single Comprehensive Cancer Center Retrospective Review of 50 Patients (2021) (0)
leukemia higher risk myelodysplastic syndrome and chronic myelomonocytic Results of a randomized study of three schedules of low-dose decitabine in (2013) (0)
Symptom Assessment in Patients with Chronic Lymphocytic Leukemia: Validation and Application of the M.D. Anderson Symptom Inventory. (2005) (0)
Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients (2013) (0)
α chromosome-positive chronic myeloid leukemia after failure of interferon- Result of high-dose imatinib mesylate in patients with Philadelphia (2013) (0)
P300 Induces STAT3 Acetylation and Provides CLL Cells with Survival Advantage (2019) (0)
LDH as Predictive Parameter in Treatment‐Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12: CLL‐094 (2018) (0)
5.39 Feasibility Analysis of Non-myeloablative Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia and 17p Deletion (2011) (0)
Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML) (2007) (0)
Poster: CLL-162 PTX3 is Constitutively Active in CLL Cells (2022) (0)
Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL). (2012) (0)
Correlation between peripheral blood and bone marrow samples for detection of PML-RARA fusion transcripts by quantitative PCR in patients with acute promyelocytic leukemia (2015) (0)
Cross-Talk between CLL Cells and Bone Marrow Endothelial Cells: Role of Signal Transducer and Activator of Transcription-3 (2014) (0)
The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype: CLL‐085 (2018) (0)
Approach to frontline therapy in elderly chronic lymphocytic leukemia patients (2013) (0)
More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia (2022) (0)
relapsed and refractory chronic lymphocytic leukemia Lenalidomide induces complete and partial remissions in patients with (2013) (0)
STAT3-induced GM-CSFRα Protects Chronic Lymphocytic Leukemia (CLL) Cells From Apoptosis (2014) (0)
Early Treatment with Ofatumumab in Patients with High-Risk CLL (2022) (0)
The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study (2022) (0)
Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs). (2019) (0)
Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12 (2012) (0)
Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). (2006) (0)
Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia (2022) (0)
O4 The hematopoietic cell transplantation comorbidity index predicts outcomes in elderly patients with acute myeloid leukemia undergoing induction therapy: a single center experience of 177 patients (2006) (0)
Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis (2013) (0)
Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL, (2011) (0)
52 Constitutive Serine Phosphorylation of STAT3 Induces Proliferation of Chronic Lymphocytic Leukemia Cells (2007) (0)
Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL). (2009) (0)
Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach (2019) (0)
Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alessandra Ferrajoli?

Alessandra Ferrajoli is affiliated with the following schools:

MD Anderson Cancer Center

Alessandra Ferrajoli's Academic­Influence.com Rankings

Alessandra Ferrajoli's Degrees

Why Is Alessandra Ferrajoli Influential?

Alessandra Ferrajoli's Published Works

Published Works

What Schools Are Affiliated With Alessandra Ferrajoli?

Alessandra Ferrajoli's AcademicInfluence.com Rankings